Despite the advent of novel targeted therapies and promising emerging strategies, acute myeloid leukemia (AML) remains difficult and challenging to treat. With a median age at diagnosis of 68 years, the incidence of AML is increasing as the general
Search Results
Novel and Emerging Treatment Strategies for Acute Myeloid Leukemia
Presented by: Eunice S. Wang
Updates in the Management of Newly Diagnosed Acute Myeloid Leukemia
Presented by: Alice S. Mims
Over the past 5 years, the treatment landscape for acute myeloid leukemia (AML) has changed remarkably, according to Alice S. Mims, MD, MS, Associate Professor, The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove
Acute Myeloid Leukemia
Vanderbilt-Ingram Cancer Center
Approximately 13,290 people will be diagnosed with acute myeloid leukemia (AML) in 2008, and 8820 patients will die of the disease. As the population ages, the incidence of AML, along with myelodysplasia, appears to be rising. Clinical trials have led to significant treatment improvements in some areas, primarily acute promyelocytic leukemia. However, recent large clinical trials have highlighted the need for new, innovative strategies, because outcomes for AML patients have not substantially changed in the past 3 decades. The NCCN AML Panel has focused on outlining reasonable treatment options based on recent clinical trials and data from basic science, which may identify new risk factors and treatment approaches. These guidelines attempt to provide a rationale for including several treatment options in some categories, as divergent opinions about the relative risks and benefits of various treatment options have surfaced. Updates for 2009 include new clarifications of some treatment recommendations as well as for defining polymerase chain reaction positivity.
For the most recent version of the guidelines, please visit NCCN.org
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt, Dale Bixby, Steven E. Coutre, Marcos De Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Thomas W. LeBlanc, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Margaret R. O’Donnell, Rebecca Olin, Deniz Peker, Alexander Perl, Daniel A. Pollyea, Keith Pratz, Thomas Prebet, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Matthew Wieduwilt, Kristina M. Gregory, OCN, Lydia Hammond, and Ndiya Ogba
Overview Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among
Monitoring Minimal Residual Disease in Acute Myeloid Leukemia: Ready for Prime Time?
Farhad Ravandi and Jeffrey L. Jorgensen
. References 1 Dohner H Estey EH Amadori S . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet . Blood 2010 ; 115 : 453 – 474 . 2 Cheson
Progressive Multifocal Leukoencephalopathy After Allogeneic Bone Marrow Transplantation for Acute Myeloid Leukemia
Hans C. Lee, Victor Mulanovich, and Yago Nieto
immunosuppression. This report presents 2 patients diagnosed with PML after receiving allogeneic BMTs for acute myeloid leukemia (AML) in the setting of significant T-cell lymphopenia. Case 1 A 69-year-old man was diagnosed with acute myelomonocytic
Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid Leukemia
Hany Elmariah and Keith W. Pratz
Background For 40 years, standard therapy for acute myeloid leukemia (AML) has remained infusional cytarabine/anthracycline–based induction chemotherapy to achieve remission, followed typically by high-dose cytarabine consolidative therapy to
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Daniel A. Pollyea, Jessica K. Altman, Rita Assi, Dale Bixby, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Brian A. Jonas, Ashwin Kishtagari, Jeffrey Lancet, Lori Maness, James Mangan, Gabriel Mannis, Guido Marcucci, Alice Mims, Kelsey Moriarty, Moaath Mustafa Ali, Jadee Neff, Reza Nejati, Rebecca Olin, Mary-Elizabeth Percival, Alexander Perl, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi, Rory Shallis, Paul J. Shami, Eytan Stein, Richard M. Stone, Kendra Sweet, Swapna Thota, Geoffrey Uy, Pankit Vachhani, Carly J. Cassara, Deborah A. Freedman-Cass, and Katie Stehman
occurs in collaboration with dermatology. It is essential to differentiate the skin lesions of BPDCN from other neoplastic and nonneoplastic skin lesions and rashes, including leukemia cutis associated with acute myeloid leukemia (AML), and analysis by
Management of Extramedullary Leukemia as a Presentation of Acute Myeloid Leukemia
Samuel J. Slomowitz and Paul J. Shami
Extramedullary presentation of acute myeloid leukemia (AML) is considered uncommon, although in one series it occurs in up to 30% of patients. 1 Extramedullary involvement usually reflects systemic disease. Very rarely extramedullary disease
Relationship Between Longitudinal Coping Strategies and Outcomes in Patients With Acute Myeloid Leukemia
Hermioni L. Amonoo, Elizabeth Daskalakis, Emma C. Deary, Monica H. Bodd, Matthew J. Reynolds, Ashley M. Nelson, Richard Newcomb, Tejaswini M. Dhawale, Daniel Yang, Selina M. Luger, Jillian L. Gustin, Andrew Brunner, Amir T. Fathi, Thomas W. LeBlanc, and Areej El-Jawahri
Background Coping with a sudden-onset life-threatening illness, intensive chemotherapy, and numerous physical adverse effects can be challenging for many patients with acute myeloid leukemia (AML). 1 , 2 The demands of treatment and recovery
